ScreenerHero

PEPGPepGen Inc. Common Stock

NAS · US · Healthcare · Biotechnology · pepgen.com
3.140USD+3.46%Mkt Cap: 217.47M $P/E: —

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap217.47M $
Enterprise Value109.06M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-89.66M $
Revenue/Share—
Last Price3.140 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees57
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.93
PEG—
EV/EBITDA-1.45
EV/Revenue—
P/S—
P/B1.76
EPS (TTM)-1.00
EPS (Forward)-1.04
52W Range
1.13030% of range7.800
52W High7.800 USD
52W Low1.130 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-60.81%
ROA-51.55%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-81.64M $
CapEx (TTM)264.00K $
FCF Margin—
FCF Yield-19.89%
Net Debt-101.14M $
Net Debt/EBITDA1.35
Balance Sheet
Debt/Equity0.12
Current Ratio13.36
Quick Ratio13.02
Book Value/Sh1.728 USD
Cash/Share1.693 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)10.19 USD
Upside (mean)+224.4%
Target Range2.500 USD – 20.00 USD
$2.500+224.4% to mean$20.00
# Analysts8
Ownership
Shares Out.69.26M
Float36.14M
Insiders0.23%
Institutions82.85%
Short Interest
Short Ratio3.9d
Short % Float8.37%
Short % Out.5.93%
Shares Short4.11M
Short (prev mo.)4.00M
Technical
SMA 502.128 (+47.6%)
SMA 2003.740 (-16.1%)
Beta1.89
S&P 52W Chg18.16%
Avg Vol (30d)1.14M
Avg Vol (10d)1.18M
Technical Indicators
RSI (14)76.4
MACD0.3046
MACD Signal0.2441
MACD Hist.+0.0604
BB Upper3.592 USD
BB Middle2.449 USD
BB Lower1.306 USD
BB Width93.32%
ATR (14)0.2026 USD
Vol Ratio (20d)0.63x